Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,016 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. Among authors: tsuboi m. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. John T, et al. Among authors: tsuboi m. J Thorac Oncol. 2023 Sep;18(9):1209-1221. doi: 10.1016/j.jtho.2023.05.015. Epub 2023 May 24. J Thorac Oncol. 2023. PMID: 37236398 Free article. Clinical Trial.
Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Tsuboi M, et al. N Engl J Med. 2023 Jul 13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. N Engl J Med. 2023. PMID: 37272535 Clinical Trial.
Early chest tube removal regardless of drainage volume after anatomic pulmonary resection: A multicenter, randomized, controlled trial.
Takamochi K, Haruki T, Oh S, Endo M, Funai K, Kitamura Y, Tsuboi M, Tsukioka T, Suzuki H, Ito H, Okumura N, Ueno T, Ikeda N, Iwata H, Okada M, Ichikawa T, Okamoto T, Nojiri S, Suzuki K; Advanced Clinical Trial Chest Surgery Group. Takamochi K, et al. Among authors: tsuboi m. J Thorac Cardiovasc Surg. 2024 Aug;168(2):401-410.e1. doi: 10.1016/j.jtcvs.2023.10.050. Epub 2023 Oct 30. J Thorac Cardiovasc Surg. 2024. PMID: 38348845 Clinical Trial.
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Among authors: tsuboi m. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
Early chest tube removal, regardless of drainage volume after anatomical pulmonary resection: a multicenter randomized controlled trial.
Takamochi K, Haruki T, Oh S, Endo M, Funai K, Kitamura Y, Tsuboi M, Tsukioka T, Suzuki H, Ito H, Okumura N, Ueno T, Ikeda N, Iwata H, Okada M, Ichikawa T, Okamoto T, Nojiri S, Suzuki K; Advanced Clinical Trial Chest Surgery Group (ACTG). Takamochi K, et al. Among authors: tsuboi m. J Thorac Cardiovasc Surg. 2023 Oct 28:S0022-5223(23)01007-3. doi: 10.1016/j.jtcvs.2023.10.050. Online ahead of print. J Thorac Cardiovasc Surg. 2023. PMID: 39492408
Prospective, Multi-Institutional Observational Study of Deterioration in Activities of Daily Living in Elderly Patients After Lung Cancer Surgery.
Takei H, Kunitoh H, Wakabayashi M, Kataoka T, Sekino Y, Mizutani T, Tsuboi M, Ikeda N, Asamura H, Okada M, Takahama M, Ohde Y, Okami J, Shiono S, Aokage K, Watanabe SI; Lung Cancer Surgical Study Group of the Japan Clinical Oncology Group, Japan. Takei H, et al. Among authors: tsuboi m. JTO Clin Res Rep. 2023 Jul 17;4(8):100550. doi: 10.1016/j.jtocrr.2023.100550. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37600227 Free PMC article.
Osimertinib in Resected EGFR-Mutated NSCLC. Reply.
Tsuboi M, Herbst RS, Wu YL. Tsuboi M, et al. N Engl J Med. 2023 Oct 5;389(14):1342. doi: 10.1056/NEJMc2309385. N Engl J Med. 2023. PMID: 37792623 No abstract available.
Risk factors for loss of pulmonary function after wedge resection for peripheral ground-glass opacity dominant lung cancer.
Miyoshi T, Ito H, Wakabayashi M, Hashimoto T, Sekino Y, Suzuki K, Tsuboi M, Moriya Y, Yoshino I, Isaka T, Hattori A, Mimae T, Isaka M, Maniwa T, Endo M, Yoshioka H, Nakagawa K, Nakajima R, Tsutani Y, Saji H, Okada M, Aokage K, Fukuda H, Watanabe SI. Miyoshi T, et al. Among authors: tsuboi m. Eur J Cardiothorac Surg. 2023 Dec 1;64(6):ezad365. doi: 10.1093/ejcts/ezad365. Eur J Cardiothorac Surg. 2023. PMID: 37930048
1,016 results